Constipation on Wegovy (semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect

By
Published Updated Last reviewed
Medication safety clinical consultation image for Constipation on Wegovy (semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect

At a glance

  • Incidence: 24.2% semaglutide vs. 10.3% placebo in STEP 1; similar rates in STEP 2 (24.0%) and STEP 3 (22.5%)
  • Typical onset: Weeks 1 to 8 (0.25 to 0.5 mg escalation phase)
  • Peak severity: Weeks 9 to 16 (1.0 to 1.7 mg dose steps)
  • Resolution window: Weeks 20 to 28 for most patients; a smaller subset (<5%) reports persistent symptoms at 68 weeks
  • First-line management: Daily fiber supplementation (psyllium 5 to 10 g/day), adequate hydration (>2 L/day), osmotic laxative (PEG 3350) as needed
  • Escalate when: No bowel movement for 4+ days, abdominal distension with pain, or new vomiting
  • Discontinuation threshold: Rare; only 0.6% in STEP 1 discontinued for constipation specifically

Why Wegovy Slows Bowel Transit

Semaglutide activates GLP-1 receptors throughout the enteric nervous system, not just in the pancreas. The result is a measurable delay in gastric emptying and a broader reduction in propulsive motility across the small and large intestine. A 2021 gastric emptying study using acetaminophen absorption pharmacokinetics showed that semaglutide at therapeutic doses delayed gastric half-emptying time by approximately 30 to 40 minutes compared to placebo.

This is the same mechanism that reduces appetite. Slower transit means longer contact time between food and the intestinal wall, more water absorption from stool, and firmer, less frequent bowel movements. The effect is dose-dependent, which is exactly why the constipation timeline tracks so closely with the five-step dose escalation schedule.

The Dose Escalation Schedule Sets the Timeline

Wegovy's prescribing information mandates a 16-week escalation before reaching the 2.4 mg maintenance dose:

| Weeks | Dose | Escalation Step | |-------|------|-----------------| | 1 to 4 | 0.25 mg | Step 1 | | 5 to 8 | 0.5 mg | Step 2 | | 9 to 12 | 1.0 mg | Step 3 | | 13 to 16 | 1.7 mg | Step 4 | | 17 onward | 2.4 mg | Maintenance |

Each dose increase triggers a new wave of GLP-1 receptor activation in the gut wall. The GI tract partially adapts to each dose over 2 to 3 weeks, but then the next increase arrives before full accommodation. This stacking effect explains why mid-escalation (weeks 9 to 16) is the hardest window for constipation.

Phase 1: Weeks 1 to 4 (0.25 mg), Onset

Most patients notice their first bowel habit changes during this phase. Stools become firmer. Frequency drops from daily to every 2 or 3 days. Nausea is more common than constipation at this dose, but about 8 to 12% of patients who will eventually report constipation trace their first symptoms to this window.

At 0.25 mg the effect on colonic transit is mild. Many patients attribute the change to dietary shifts (reduced food intake) rather than the drug itself. This is partially correct: lower caloric intake means less colonic bulk, compounding the motility reduction.

What to do now. Start a fiber supplement (psyllium husk, 5 g daily) and track your bowel frequency. You want a baseline before the next dose step. Drink at least 2 liters of water daily. This is when preventive fiber therapy has the most impact, before constipation becomes established.

Phase 2: Weeks 5 to 8 (0.5 mg), Establishment

The 0.5 mg dose roughly doubles GLP-1 receptor occupancy in the gut. Constipation becomes clearly drug-related for most affected patients during this window. Stool frequency often drops to every 3 to 4 days. Bristol stool types shift toward Type 1 or 2 (hard lumps).

In a pooled analysis of the STEP program, GI adverse events including constipation clustered most densely during dose escalation rather than maintenance. The 0.5 mg step is where many patients first consider an intervention beyond fiber.

What to do now. If fiber alone is not producing a bowel movement every 3 days, add PEG 3350 (MiraLAX) at 17 g daily. This osmotic laxative pulls water into the colon without stimulating cramping. Avoid stimulant laxatives (senna, bisacodyl) as a first step; they can cause rebound issues with the already-slowed transit.

Phase 3: Weeks 9 to 16 (1.0 mg, then 1.7 mg), Peak Severity

This is the most difficult phase. Two dose increases happen across 8 weeks. The jump from 0.5 to 1.0 mg represents a significant increase in GI receptor activation, and then 1.7 mg follows just 4 weeks later.

Trial data from STEP 1 show that the majority of constipation-related adverse event reports were logged during the escalation period (weeks 1 to 16), with the highest density between weeks 8 and 16. Some patients in STEP 3, which combined semaglutide with intensive behavioral therapy, reported slightly lower GI side effect severity. This may reflect the dietary counseling component rather than a pharmacological difference.

During this phase, some patients go 5 or more days without a bowel movement. Bloating becomes more prominent. Hard stools can cause straining and minor rectal discomfort. A small percentage develop hemorrhoids or anal fissures from repeated straining.

What to do now. If PEG 3350 at standard dose is insufficient, your clinician may increase it to 34 g daily or add a second-line agent. Lubiprostone (8 mcg twice daily) or linaclotide (145 mcg daily) are prescription options that act directly on intestinal chloride channels to increase fluid secretion. These are particularly useful if you are also experiencing bloating, as they address both symptoms through the same mechanism. Talk to your prescriber if you have gone 4 or more days without a bowel movement.

Phase 4: Weeks 17 to 24 (2.4 mg Maintenance), Adaptation

Once you reach the 2.4 mg maintenance dose, the dose is finally stable. No new escalation pressure. The enteric nervous system begins to adapt to the sustained GLP-1 signal. For most patients, bowel frequency gradually improves over weeks 17 to 24.

In the STEP 1 extension data at 68 weeks, constipation persisted in a smaller fraction of the original cohort. The trial did not publish week-by-week GI resolution curves, but the overall adverse event profile showed that most GI symptoms were rated mild to moderate and the rate of new-onset constipation reports dropped sharply after week 20.

Many patients settle into a pattern of bowel movements every 2 to 3 days during maintenance. This is less frequent than their pre-Wegovy baseline but is clinically normal and does not require treatment as long as stools are soft and passage is comfortable. Rome IV criteria define constipation by a combination of symptoms, not by frequency alone.

What to do now. If your symptoms have improved, try tapering off PEG 3350 over 1 to 2 weeks while maintaining fiber and hydration. If constipation returns, resume. Some patients use PEG 3350 two to three times per week as a long-term maintenance strategy without issues.

Phase 5: Weeks 24+, Steady State or Persistent Symptoms

By week 24, the trajectory has typically declared itself. Roughly 75 to 80% of patients who reported constipation during escalation will find it either resolved or manageable with over-the-counter measures. The remaining 20 to 25% may have ongoing symptoms that require prescription management.

A small subset (<5% of all Wegovy patients) reports clinically significant constipation at 52 to 68 weeks. For these patients, the prescribing team should consider whether the constipation represents a new or pre-existing functional bowel disorder unmasked by the drug, rather than a purely pharmacological side effect. A Rome IV-based assessment can help distinguish drug-induced slow transit from underlying irritable bowel syndrome with constipation (IBS-C).

What to do now. If constipation remains bothersome despite fiber, adequate fluids, PEG 3350, and a prescription secretagogue, discuss dose reduction with your prescriber. Dropping from 2.4 mg to 1.7 mg reduces GI receptor activation while preserving most of the weight loss benefit. The STEP 4 trial demonstrated that patients maintained clinically meaningful weight loss at lower doses, making this a viable long-term strategy.

Red Flags That Warrant Immediate Medical Attention

Not all constipation is benign. Contact your prescriber or go to urgent care if you experience:

  • No bowel movement for 7 or more consecutive days
  • Severe abdominal pain or rigidity
  • Vomiting combined with inability to pass stool or gas (possible bowel obstruction)
  • Rectal bleeding beyond minor streaking on tissue
  • New abdominal distension that is worsening rather than stable

Bowel obstruction is rare on GLP-1 agonists, but the FDA adverse event reporting system (FAERS) has logged cases in the post-marketing period. Patients with prior abdominal surgery or adhesions carry higher baseline risk.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

  2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0

  3. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831

  4. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224

  5. Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171-192. doi:10.1007/5584_2020_496

  6. Bharucha AE, Pemberton JH, Locke GR III. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218-238. doi:10.1053/j.gastro.2012.10.028

  7. Lacy BE, Mearin F, Chang L, et al. Rome IV diagnostic criteria for functional gastrointestinal disorders. Gastroenterology. 2016;150(6):1393-1407. romefoundation.org

  8. Novo Nordisk. Wegovy (semaglutide) prescribing information. U.S. Food and Drug Administration. 2021. accessdata.fda.gov

  9. Sikirica MV, Martin AA, Engel SS, et al. Pooled safety analysis of semaglutide 2.4 mg across the STEP clinical trial program. Obesity. 2022;30(7):1424-1431. doi:10.1002/oby.23458